The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...

The FDA rejected Sanofi's MS drug tolebrutinib, citing liver injury risks, unclear benefits, and trial data that failed to ...

Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...

Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the ...

Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently ...

A new study by researchers in the Department of Clinical Neuroscience, Karolinska Institutet, has identified 18 potential drug targets for the treatment of multiple sclerosis. The study may pave the ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

A new study has discovered a possible biomarker linked to multiple sclerosis disease progression that could help identify ...

Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple ...